Shares of GTx, Inc. (NASDAQ:GTXI) have received an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation.
Brokerages have set a 1 year consensus price target of $7.00 for the company and are expecting that the company will post ($0.57) EPS for the current quarter, according to Zacks. Zacks has also given GTx an industry rank of 127 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded shares of GTx from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Tuesday, January 3rd.
Shares of GTx (NASDAQ:GTXI) traded down 10.29% during trading on Friday, hitting $5.32. 3,604 shares of the stock were exchanged. The company’s market cap is $84.69 million. The firm’s 50-day moving average is $5.87 and its 200 day moving average is $1.99. GTx has a 1-year low of $5.00 and a 1-year high of $11.19.
GTx (NASDAQ:GTXI) last issued its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.05). Equities analysts forecast that GTx will post ($1.34) earnings per share for the current fiscal year.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Get a free copy of the Zacks research report on GTx (GTXI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com